Welcome to our dedicated page for Bon Natural Life news (Ticker: BON), a resource for investors and traders seeking the latest updates and insights on Bon Natural Life stock.
Bon Natural Life Limited (NASDAQ: BON) is a Cayman Islands company active in the natural, health, and personal care industries, with operations centered in Xi’an, China. Company news frequently describes Bon as a bio-ingredient solution provider focused on functional active ingredients extracted from natural herb plants, fragrance compounds, health supplements, and bioactive food ingredients.
The BON news feed highlights developments across several product and technology areas. Investors and analysts can follow announcements on fragrance compounds such as ambroxide and related natural fragrance ingredients, including distribution agreements targeting the Asia-Pacific and industrial fabric fragrance markets. News also covers health supplement (powder drink) launches and cooperation agreements for natural prebiotic series and “prebiotic + postbiotic” gut health products centered on super prebiotic stachyose.
Another recurring theme in BON’s news is its work with tea pigment-based digestive health products and kombucha-inspired beverages. The company reports on strategic sales agreements in Greater China for second-generation tea pigment digestive health products and high-tea-pigment beverages produced through controlled fermentation using SCOBY cultures. These updates provide insight into Bon’s positioning in digestive wellness and functional beverage segments.
Bon Natural Life also issues news about its Apple Series metabolic health products based on apple polyphenols and plant proteins, as well as about its AI-powered new drug R&D platform that screens natural and TCM-derived compounds for weight management and other therapeutic potential. Regulatory and corporate governance items, such as Nasdaq compliance notifications and senior management changes, are disclosed through press releases and corresponding Form 6-K filings.
By reviewing BON news on this page, users can track product pipeline updates, distribution partnerships, AI-driven research milestones, and listing status disclosures that shape the company’s business trajectory.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Bon Natural Life Limited (Nasdaq: BON) announced the appointment of Mr. Wallace Lee as Chief Financial Officer (CFO), effective April 17, 2023. He succeeds Zhenchao Li, who has served as CFO for four years. Mr. Lee brings over 16 years of financial experience, including roles as CFO at China SXT Pharmaceuticals and Vice President of Finance at Ruanyun Edi Technology. His expertise is expected to drive BON's growth in the natural health and personal care sectors. In his statement, Mr. Lee expressed his honor to join BON’s leadership and focus on both domestic and international market growth.
Richard Hu, a member of the executive team, emphasized Mr. Lee's strategic and operational experience as key to BON's ambitions. The company specializes in manufacturing personal care ingredients and health supplements.
Bon Natural Life Limited (Nasdaq: BON) reported a 17.3% revenue increase for the fiscal year 2022, reaching $29.9 million. The net income rose by 35.4% to $6.2 million, translating to $0.74 per diluted share. The company's gross profit saw a 32.5% rise to $9.4 million, and gross margin improved to 31.5%. Significant growth was noted in bioactive food ingredients, with revenue and gross profits increasing by 48.5% and 61.4%, respectively. Management anticipates further growth with the upcoming Yumen Plant expected to boost annual revenues by 150% once operational. The full results were discussed in a live webinar on February 10, 2023.
Bon Natural Life Limited (Nasdaq: BON) is set to release its FY2022 earnings report before market opens on February 10, 2023. The earnings will cover the fiscal year ending September 30, 2021. Alongside the release, the company will conduct an investor conference call at 9:00 a.m. EST, featuring key executives including CEO Richard Hu and CFO Zhenchao Li. The call will be available via pre-registration and can also be accessed later as an archived recording. Bon Natural focuses on producing bio-ingredient solutions for the health and personal care sectors, including plant extracts and bioactive food products.
Bon Natural Life Limited (Nasdaq: BON) announced a delay in the initial production target for its new Yumen Plant from Q4 2022 to May 2023. The construction, which began in July 2021, faced challenges due to strict COVID-19 protocols, logistic disruptions, and labor shortages. Despite completing the building structure in May 2022, interior outfitting and equipment installation were hindered. CEO Richard Hu expressed confidence in the plant's potential to enhance production of fragrance compounds and bioactive food ingredients amid ongoing pandemic-related uncertainties.
Bon Natural Life Limited (Nasdaq: BON) reported a 17.0% revenue increase to US$13.7 million for 1H-2022. Gross profit rose 19.6% to US$4.0 million, with a gross margin of 29.5%. Notably, bioactive food ingredient sales surged 171.8%, while health supplements fell 28.5%. Net income improved by 10.2% to US$2.5 million, although diluted EPS decreased to $0.30 from $0.40 year-over-year. The company is expanding production capabilities with the Yumen plant, set to boost capacity by 200%.
Bon Natural Life Limited (Nasdaq: BON) will release its half-year earnings for the period ending March 31, 2022, on August 1, 2022, before market open. The company also plans to host an investor conference call at 9:00 a.m. EST on the same day, featuring key executives. The call will be accessible via pre-registration or through provided dial-in options. BON specializes in bio-ingredient solutions for personal care and health products. For further insights, investors can access the webcast through the company's investor website.